MITO - Stealth BioTherapeutics Does The Deal With Alexion And Other Headlines: The Good Bad And Ugly Of Biopharma
On the good news front in today's series, Stealth BioTherapeutics (MITO) and Alexion Pharmaceuticals (ALXN) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics' lead product candidate, which is being investigated in late stage clinical studies in three primary mitochondrial diseases - primary mitochondrial myopathy (PMM - an inherited disorder), Barth syndrome (enlarged & weakened heart) and Leber’s hereditary optic neuropathy (LHON - an inherited vision loss), and in an earlier stage clinical study in dry age-related macular degeneration (dry-AMD).
It